

Mongolia

Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Mongolia							
2.	Vaccine grai	Vaccine grant number: 15-MNG-08h-Y, 1518-MNG-25b-X, 19-MNG-25b-X							
3.	Date of Deci	Date of Decision Letter: 07/06/2019							
4.	Date of the F	Date of the Partnership Framework Agreement: 7/Apr/15							
5.	Programme	Programme title: New Vaccine Support (NVS), Inactivated Polio Virus, Routine							
6.	Vaccine type: Inactivated Polio Virus								
7.	Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID								
8.	Programme Duration: ¹ 2015-2019								
9.	Programme Budget (indicative): ² (subject to the terms of the Partnership Framework Agreeme applicable)								
		2015-2018	2019	2020	2021	2022	2023	Total ²	
	Programme Budget (US\$)	195,153	66,000	-	-	-	-	261,153	
10.	10. Vaccine introduction grant								
	Approval								
	Year		Grant Number		Amount (US\$)				
		2015	15-MNC	G-08h-Y		100,000]		
11.	Product switch grant Not applicable								
12.	Indicative A	nnual Amount	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	Type of supplies to be purchased with Gavi funds			2015-2018		2019		2020	
				20.0 20.0				2020	
	Number of vaccine doses					22,100		-	
	Annual Amounts (US\$)		195,153 66,000			-			
13.	Procuremen	Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
14.	Self-procure	ement:	Not applicable	е					

¹ This is the entire duration of the Programme.

 $^{^{\}rm 2}\,{\rm This}$ is the total amount endorsed by Gavi for the entire duration of the Programme.

 $^{^{\}rm 3}\,{\rm This}$ is the total amount approved by Gavi.



15. Co-financing obligations:

Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

		Due dates
	or the annual procurement of vaccines, Country shall submit ormation each year:	the
•	Vaccine stock levels including buffer stock, by end of March	n; 31 March 2019
•	Number of children to be vaccinated, wastage rates, any prochanges in product, presentation or use, or minimum co-final levels and vaccines received, by mid-May.	,
•	Countries shall report the actual switch date in the first renerequest following the actual implementation.	wal
	ce with applicable Gavi processes, Country shall report To b natic and financial performance.	e agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

Stook F. K brill

7 June 2019